Core Insights - Harrow has announced that three scientific abstracts related to its products VEVYE and ILEVRO have been accepted for presentation at the ASCRS 2026 Annual Meeting, highlighting the company's commitment to advancing treatment options for ophthalmic diseases [1][2]. Company Overview - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products for various eye conditions, including dry eye disease, cataracts, and glaucoma [4]. Research Presentation Details - The abstracts will be presented in specific sessions at the ASCRS Annual Meeting, focusing on ocular surface disease and medications related to cataract surgery [2]. - The presentations include a post-hoc analysis of ILEVRO's effectiveness in reducing visual acuity loss associated with cataract surgery and real-world treatment patterns for VEVYE in dry eye disease [6]. Commitment to Evidence-Based Treatment - The acceptance of these abstracts underscores Harrow's ongoing commitment to evidence-based treatment options for ophthalmic diseases, particularly in addressing complications from cataract surgery and dry eye disease [2].

Core Insights - Harrow is launching the Harrow Access for All (HAFA) program to enhance patient access to its ophthalmic medications, building on the success of the VEVYE Access for All (VAFA) initiative [1][2][4] Summary by Sections HAFA Program Overview - HAFA aims to provide a unified access point for Harrow's comprehensive ophthalmic portfolio, including branded, authorized generics, and compounded medications, set to launch in late 2025 [3][4] - The program is designed to improve affordability and streamline the prescribing process, ultimately supporting better patient outcomes and greater efficiency for physicians [3][4] Program Highlights - Eligible commercially insured patients may pay as little as $0, with out-of-pocket costs capped at $59 for all eligible patients, ensuring affordability regardless of coverage status [5] - HAFA will be implemented in three phases, with Phase 1 launching in Q4 2025, covering the majority of Harrow's specialty product portfolio [5] - Phase 2 is expected in the first half of 2026, expanding the portfolio of authorized generics, while Phase 3 in 2027 will extend across Harrow's full range of specialty, AGx, and compounded medicines [5] Technology and Efficiency - The HarrowAccess.com portal will streamline the prescribing process, allowing prescribers to manage prescriptions efficiently and reducing administrative burdens [10] - The platform will integrate with providers' EMR systems, ensuring automatic access to HAFA benefits for patients without additional steps [7][10] Commitment to Patient Access - The CEO of Harrow emphasized the company's commitment to reducing access barriers in ophthalmology, aiming to ensure that every patient can access sight-preserving medications without delay [4] - The program is seen as a significant step towards addressing the challenges of access and affordability in prescription medications, which have been longstanding issues in the industry [7]